AR128568A1 - METHODS TO TREAT MYOSITIS THROUGH THE USE OF FCRN ANTAGONISTS - Google Patents
METHODS TO TREAT MYOSITIS THROUGH THE USE OF FCRN ANTAGONISTSInfo
- Publication number
- AR128568A1 AR128568A1 ARP230100395A ARP230100395A AR128568A1 AR 128568 A1 AR128568 A1 AR 128568A1 AR P230100395 A ARP230100395 A AR P230100395A AR P230100395 A ARP230100395 A AR P230100395A AR 128568 A1 AR128568 A1 AR 128568A1
- Authority
- AR
- Argentina
- Prior art keywords
- myositis
- subject
- fcrn
- methods
- antagonist
- Prior art date
Links
- 201000002481 Myositis Diseases 0.000 title abstract 7
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 title abstract 5
- 239000005557 antagonist Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 101150050927 Fcgrt gene Proteins 0.000 title 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108010068617 neonatal Fc receptor Proteins 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En la presente descripción se proporcionan métodos para tratar la miositis mediante el uso de una cantidad eficaz de un antagonista del receptor de Fc neonatal (FcRn) humano. También se proporcionan en la presente descripción antagonistas de FcRn para su uso en el tratamiento de la miositis y para su uso en la fabricación de un medicamento para el tratamiento de la miositis. Reivindicación 73: Un método para tratar la miositis en un sujeto, el método comprende: administrar al sujeto una cantidad eficaz de un segundo antagonista de FcRn, en donde la miositis ha recaído en el sujeto después de la terapia previa con un primer antagonista de FcRn y en donde el sujeto tiene un nivel en suero de un MAA o un MSA que es mayor que o igual a un valor de referencia asociado con la miositis en el sujeto.Provided herein are methods of treating myositis by using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. Also provided herein are FcRn antagonists for use in the treatment of myositis and for use in the manufacture of a medicament for the treatment of myositis. Claim 73: A method of treating myositis in a subject, the method comprising: administering to the subject an effective amount of a second FcRn antagonist, wherein the myositis has relapsed in the subject after prior therapy with a first FcRn antagonist and wherein the subject has a serum level of a MAA or an MSA that is greater than or equal to a reference value associated with myositis in the subject.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063269430P | 2020-03-16 | 2020-03-16 | |
| US202063365824P | 2020-06-03 | 2020-06-03 | |
| US202063407369P | 2020-09-16 | 2020-09-16 | |
| US202263268312P | 2022-02-21 | 2022-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128568A1 true AR128568A1 (en) | 2024-05-22 |
Family
ID=91274952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100395A AR128568A1 (en) | 2020-03-16 | 2023-02-17 | METHODS TO TREAT MYOSITIS THROUGH THE USE OF FCRN ANTAGONISTS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR128568A1 (en) |
-
2023
- 2023-02-17 AR ARP230100395A patent/AR128568A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021016833A2 (en) | Compounds with ferroptosis-inducing activity and methods of their use | |
| MX2024012807A (en) | RUR20KD-IL-2 SELECTIVE Treg STIMULATOR AND RELATED COMPOSITIONS | |
| MX2025000166A (en) | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof | |
| MX2021006238A (en) | METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY. | |
| MX392869B (en) | Kit for treating or relieving pain at incision site following surgical procedure | |
| MX2016015346A (en) | CANCER TREATMENT METHODS WITH ANTAGONISTS AGAINST SCHEDULED DEATH 1 (PD-1) AND PROGRAMMED DEATH LINK 1 (PD-L1) IN COMBINATION WITH RADIOTHERAPY. | |
| MX2021005024A (en) | TREATMENT METHODS USING SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CELL MATURATION ANTIGEN B. | |
| AR095197A1 (en) | COMBINATION OF AN EGFR T790M INHIBITOR AND EGFR INHIBITOR FOR THE TREATMENT OF PULMONARY CANCER OF NON-SMALL CELLS | |
| BR112020015915A8 (en) | USES OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA4 ANTIBODY OR ANTIGEN-BINDING FRAGMENTS THEREOF, AS WELL AS A KIT FOR TREATMENT OF A PATIENT WITH CANCER | |
| HRP20230504T1 (en) | Activin-actrii antagonists and uses for treating myelodysplastic syndrome | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| BR112019005351A2 (en) | combination therapy with controlled release cnp agonists | |
| BR112018067923A2 (en) | Cancer treatment methods using pd-1 axis binding antagonists and anti-gpc3 antibodies | |
| MX2024010165A (en) | METHODS FOR TREATING MYOSITIS USING FCRN ANTAGONISTS. | |
| BR112018070017A2 (en) | Pediatric Cancer Treatment Methods | |
| AR131601A1 (en) | Methods for treating primary Sjogren's syndrome using FcRn antagonists | |
| MX2019008621A (en) | Therapeutic and neuroprotective peptides. | |
| CL2024003729A1 (en) | Combination therapy of anti-PD-1 active agent, anti-TIM-3 active agent, and anti-LAG-3 active agent to treat cancer. | |
| WO2016060917A3 (en) | Formulations for histatin therapeutics | |
| CO2022013055A2 (en) | Tafoxiparin for the treatment of pre-eclampsia | |
| AR128568A1 (en) | METHODS TO TREAT MYOSITIS THROUGH THE USE OF FCRN ANTAGONISTS | |
| MY200960A (en) | Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury | |
| EA202190360A1 (en) | COMBINATION THERAPY | |
| MX2022006883A (en) | USE OF ISATUXIMAB FOR THE TREATMENT OF RECLAPSING AND/OR REFRACTORY MULTIPLE MYELOMA. | |
| BR112021018138A2 (en) | Therapeutic methods and compositions for treating lymphoma using 6,8-bis-benzylthiooctanoic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |